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Abstract
Background
Cervical cancer is the fourth leading cause of cancer death in women, with 85% of cases
and deaths occurring in developing countries. While organized screening programs have
reduced cervical cancer incidence in high-income countries through detection and treat-
ment of precancerous lesions, the implementation of organized screening has not been
effective in low-resource settings due to lack of infrastructure and limited budgets. Our
objective was to estimate the cost of comprehensive primary and secondary cervical can-
cer prevention in low- and middle-income countries.
Methods and Findings
We performed a modeling analysis to estimate 1) for girls aged 10 years, the cost of 2-dose
human papillomavirus (HPV) vaccination; and 2) for women aged 30 to 49 years, the cost
of cervical cancer screening (with visual inspection with acetic acid (VIA), HPV testing, or
cytology) and preventive treatment in 102 low- and middle-income countries from 2015 to
2024. We used an Excel-based costing and service utilization model to estimate financial
costs (2013 US$) based on prevalence of HPV, prevalence of precancerous lesions, and
screening test performance. Where epidemiologic data were unavailable, we extrapolated
from settings with data using an individual-based microsimulation model of cervical carcino-
genesis (calibrated to 20 settings) and multivariate regression. Total HPV vaccination costs
ranged from US$8.6 billion to US$24.2 billion for all scenarios considered (immediate, 5-
year, or 10-year roll-out; price per dose US$4.55-US$70 by country income level). The total
cost of screening and preventive treatment ranged from US$5.1 billion (10-year roll-out,
screening once at age 35 years) to US$42.3 billion (immediate roll-out, high intensity
screening). Limitations of this analysis include the assumption of standardized protocols by
country income level that did not account for the potential presence of multiple screening
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Conclusions
The estimated cost of comprehensive cervical cancer prevention with 2-dose HPV vaccina-
tion of 10-year-old girls and screening of women aged 30 to 49 years ranges from US$13.7
billion to US$66.5 billion, depending on speed of roll-out, vaccine price per dose, and
screening test and frequency. Findings demonstrate the substantial impact of vaccine price
in middle-income countries that are not eligible for assistance from Gavi, the Vaccine Alli-
ance. Replacing routine cytology with HPV-based screening may reduce total costs. Data
on the health impact and relative cost-effectiveness of strategies are needed to determine
the best value for public health dollars.
Introduction
Cervical cancer is the fourth most common cancer in women, resulting in an estimated
528,000 incident cases and 266,000 deaths worldwide in 2012 [1]. While organized screening
programs have reduced cervical cancer incidence in high-income countries through detection
and treatment of precancerous lesions, the implementation of organized screening has not
been effective in low-resource settings due to the lack of health delivery infrastructure and lim-
ited financial resources. Approximately 85% of cases and deaths occur in low- and middle-
income countries (LMIC) [1], often affecting young women who are critical to social and eco-
nomic stability.
New opportunities to reduce preventable deaths from cervical cancer stem from two human
papillomavirus (HPV) vaccines—bothwith high efficacy against HPV types 16 and 18 (HPV-
16/18), which cause approximately 70% of cervical cancers—and point-of-care HPV-based
testing designed for low-resource settings [2–4]. In 2013, Gavi, the Vaccine Alliance began pro-
viding support for HPV-16/18 vaccines to eligible countries to increase access to vaccination
where the disease burden and financial need are greatest [5]. Screeningwith HPV testing and
visual inspectionwith acetic acid (VIA) have been demonstrated to be effective [6–8] and
potentially cost-effective [9] in low-resource settings, allowing for fewer follow-up visits (e.g.,
screen-and-treat approaches) and, in the case of HPV testing, automated processing of labora-
tory specimens that reduces resource and quality control requirements. Moreover, theWorld
Health Organization has recently recommended the use of HPV testing or VIA for cervical
cancer screening in those regions and countries that have not already established an effective,
high-coverage Pap-based program [10].
In 2015, there were nearly 50 million 10-year-old girls and 760 million women of screening
age in LMIC. To design and coordinate HPV vaccination and cervical cancer screening pro-
grams, decisionmakers must consider many attributes and outcomes associated with available
prevention strategies, including: 1) feasibility, related to human resources, infrastructure, and
financial capacity; 2) the likelihood of acceptability and political support; 3) health and eco-
nomic impact; and 4) short- and long-term affordability.
Motivated by the need for information on financial cost requirements by those making
immunization and screening policy recommendations—including theWorld Health Organiza-
tion (WHO), financing coordinationmechanisms (e.g., Gavi, the Vaccine Alliance; the Pan
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Supporting Information. The CERVIVAC model was
developed in collaboration with the Pan American
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Abbreviations: CIN, cervical intraepithelial
neoplasia; EAP, East Asia and Pacific region; ECA,
Europe and Central Asia region; GDP, gross
domestic product; GNI, gross national income;
HPV, human papillomavirus; HPV-VIA, human
papillomavirus testing followed by triage with
visual inspection; LAC, Latin America and
Caribbean region; LEEP, loop electrosurgical
excision procedure; LI, low-income countries; LMI,
lower-middle-income countries; LMIC, low- and
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acid; WHO, World Health Organization.
AmericanHealth Organization [PAHO] Revolving Fund), and potential donors—our objective
was to estimate the financial cost of scaling up coverage of primary and secondary cervical can-
cer prevention for the total target population of women in LMIC from 2015 to 2024.
Methods
Analytic overview
We used a model-based approach to synthesize population and demographic data from 102
low- and middle-income countries, coupled with country-specificepidemiologic data. The
Excel-basedCERVIVAC model was used to project the costs of HPV-16/18 vaccination of pre-
adolescent girls aged 10 years and screening of adult women aged 30 to 49 years, by income tier
andWorld Bank region, under various scenarios of years to roll-out, vaccine price per dose,
screening test, and screening frequency. Because epidemiologic data on the prevalence of HPV
and precancerous lesions are not available in all countries, we estimated these inputs using
multivariate regression models and extrapolating from an individual-basedmicrosimulation
model that was previously calibrated to 20 of the LMIC of interest.
This analysis was conducted from a payer perspective, including all direct medical costs
(including but not limited to the price of the vaccine and screening tests) for pre-adolescent
HPV vaccination, screening, and relevant diagnosis and treatment of precancerous lesions. We
present both undiscounted costs and future costs discounted at an annual rate of 3% in 2013
US dollars (US$).
CERVIVAC Model
The CERVIVAC model was developed for PAHO’s ProVac Initiative as a tool to enable Latin
America and Caribbean country teams to conduct local cost-effectiveness analysis of cervical
cancer prevention. CERVIVAC contains separate modules for evaluating the costs associated
with vaccination and screening and treatment. The model, programmed usingMicrosoft Excel
and Visual Basic for Applications 2007 (Microsoft Corporation, Redmond,WA), tracks multi-
ple female birth cohorts starting at a target age (e.g., 10 years for HPV vaccination; 30 years for
screening), projecting cost outcomes associated with HPV vaccination and screening and treat-
ment by counting events that involve resource utilization and multiplying these events by a
country-specificunit cost.
The HPV vaccination module counts the cost per dose and vaccine delivery costs, while the
screeningmodule counts the costs of screening visits, follow-up visits in triage strategies, cryo-
therapy, diagnostic confirmation with colposcopy for cytology (i.e., Pap)-based strategies and
for women who are not eligible for screen-and-treat cryotherapy, and loop electrosurgical exci-
sion procedures (LEEP). Resource utilization associated with screening is driven by screening
test characteristics (i.e., sensitivity and specificity),HPV prevalence, and the prevalence of pre-
cancerous lesions. We did not include costs associated with treatment of cervical cancer, as our
objective was to estimate costs associated with prevention.
We included LMIC with population size greater than 1 million persons.We excluded coun-
tries that were missing basic data (e.g., United Nations population data, gross national income
[GNI] per capita, WHO CHOICE facility visit cost estimates). The comprehensive list of 102
countries, stratified by income tier according to GNI per capita (Atlas method, 2013 US$),[11]
is shown in Table A in S1 File; LowerMiddle Income (LMI) and Upper Middle Income (UMI)
countries have been further stratified at the midpoint GNI per capita into LMI1 and LMI2 and
UMI1 and UMI2, respectively. Country stratification by world region is displayed in Table B
in S1 File.
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Population and epidemiologic input data
For each country, demographic estimates were from the United Nations World Population
Prospects 2012 data [12]. We estimated the number of females alive in each of the 102 coun-
tries, in each single year of age, and in each calendar year from 2015 to 2024. Each cohort was
then tracked to capture relevant health service utilization associated with either HPV vaccina-
tion of 10-year old girls or screening of women aged 30 to 49 years from 2015 to 2024. As such,
no scenarios involved combining both vaccination and screening within the same birth cohort.
To estimate HPV prevalence in countries without epidemiologic survey data, we con-
structedmultivariate regression models using previously published methods[13].We included
the following variables in the regression models to predict HPV prevalence in countries with
available data: country income classification (low, lower middle, upper middle) [11]; geo-
graphic region (Central and South America, Eastern Europe, Asia, North Africa, and sub-Saha-
ran Africa) [11]; and age-specific cervical cancer incidence in ten-year age groups (age 25 to 34
years; age 35 to 44 years; age 45 to 54 years, age 55 to 64 years) from registry data when avail-
able (N = 99) [14]; else from Globocan 2012 (N = 16) [1]. The model was restricted to LMIC to
control for the impact of screening. Generalized linear modeling for proportions with binomial
family and log link was employed to assess the relationship betweenHPV prevalence and pre-
dictor variables. Four models were created (for women age 30 to 34 years; 35 to 39 years; 40 to
44 years; and 45 to 49 years). The models were then used to predict age-specificHPV preva-
lence for countries without prevalence survey data. Models were examined for goodness of fit,
leverage, and normality. We describe adjustments for outliers in the S1 File; HPV prevalence
inputs are presented in Table C in S1 File.
To estimate prevalence of precancerous lesions, we utilized an existing microsimulation
model of cervical carcinogenesis to discern the typical relationship (i.e., age-specific ratio)
between 1) cervical intraepithelial neoplasia grade 1 (CIN1) prevalence and oncogenic HPV
prevalence; and 2) cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) prevalence and
detected cancer incidence in the absence of screening and treatment. We selected these rela-
tionships given the association of CIN1 and CIN2/3 with HPV infection and cervical cancer
incidence, respectively, for which we have empirical data in many countries. The previously
describedmicrosimulationmodel has been calibrated to epidemiologic data from the following
low- and middle-income settings: Argentina, Brazil, China, Colombia, Costa Rica, Haiti, India,
Kenya, Lebanon,Mexico, Mozambique, Nigeria, Peru, South Africa, Tanzania, Thailand, Tur-
key, Uganda, Vietnam, Zimbabwe [15–22].
To determine the relationship between prevalence of CIN1 and HPV prevalence, we used
microsimulationmodel output from each of the 20 calibrated countrymodels to determine the
median age-specific ratio of CIN1 prevalence to oncogenic HPV prevalence for women aged
30 to 49 years. We applied this ratio to actual or predicted age-specificHPV prevalence
(Table C in S1 File) to estimate age-specificCIN1 prevalence in each country in the analysis.
The ratios applied to HPV prevalence for each age group were as follows: 0.36 (age 30 to 34);
0.39 (age 35 to 39); 0.41 (age 40 to 44); and 0.41 (age 45 to 49).
To determine the relationship betweenCIN2/3 prevalence and cancer incidence, we used
microsimulationmodel output from each of the 20 calibrated countrymodels to determine the
median age-specific ratio of CIN2/3 prevalence to detected cancer incidence for women aged
30 to 49 years. We applied this ratio to age-specific cancer incidence in 5-year intervals from
Globocan 2012 [1] (Table D in S1 File) to estimate age-specificCIN2/3 prevalence in each
country in the analysis. The ratios applied to cancer incidence rate per woman for each age
group were as follows: 85.9 (age 30 to 34); 49.3 (age 35 to 39); 29.8 (age 40 to 44); and 22.0 (age
45 to 49). Applying these ratios to Globocan 2012 cancer incidence rates led to CIN2/3
Resources Required for Cervical Cancer Prevention
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prevalence estimates of 1–2% on average across countries, consistent with estimates reported
in the literature [4,8,23–28].
Vaccination and screening scenarios
We assumed 2-dose HPV vaccination, as recommended by theWHO [29], of girls aged 10
years. Screening scenarios were based on country income classification andWHO guidelines
[10]. Seven scenarios reflect levels of intensity ranging from once in a lifetime screening at age
35 (Scenario 1) to HPV-based screening at 5-year intervals in all but the Low Income (LI)
countries, where VIA would be offered every three years for women of screening age (Scenario
7) (Table 1). For countries in the LMI2 income tier and higher, strategies may vary by the pres-
ence of an existing Pap program if coverage exceeds 40% [30,31]. Scenarios 4 and 6 are identi-
cal to Scenarios 3 and 5 (respectively), with the exception that Pap testing has been replaced by
HPV-based testing in countries with Pap programs. With the exception of countries with exist-
ing Pap programs with coverage greater than 40%, screening strategies did not depend on exist-
ing screeningmodality or coverage level in a given country, but rather on income tier.
We assumed the following three roll-out strategies for both vaccination and screening: 1)
100% immediate coverage from 2015 to 2024 (Immediate Roll-out); 2) 20% coverage in 2015,
40% coverage in 2016, 60% coverage in 2017, 80% coverage in 2018, and 100% coverage of the
target population from 2019 to 2024 (5-year Roll-out); and 3) 10% coverage in 2015, 20% cov-
erage in 2016, 30% coverage in 2017, 40% coverage in 2018, 50% coverage in 2019, 60% cover-
age in 2020, 70% coverage in 2021, 80% coverage in 2022, 90% coverage in 2023, and 100%
coverage of the target population in 2024 (10-year Roll-out).We assumed these scenarios irre-
spective of a country’s existing immunization and screening program coverage.
Table 1. Screening strategies, by income tier.a
Income tier Existing
Cytology-
based
Programb
Screening scenario
Scenario 1:
Onetime
screening
Scenario 2:
Minimal
intensity
Scenario 3:
Lower
intensity w/
Pap
Scenario 4:
Lower
intensity w/o
Pap
Scenario 5:
Higher
intensity w/
Pap
Scenario 6:
Higher
intensity w/o
Pap
Scenario 7:
HPV-based
screening
Low income (LI)
(< $1045)
No VIA 1x VIA Q10 VIA Q5 VIA Q5 VIA Q3 VIA Q3 VIA Q3
Lower-middle
income 1 (LMI1)
($1046–$2585)
No VIA 1x VIA Q10 VIA Q5 VIA Q5 VIA Q3 VIA Q3 HPV Q5
Lower-middle
income 2 (LMI2)
($2586–$4125)
No VIA 1x VIA Q10 VIA Q3 VIA Q3 HPV Q5 HPV Q5 HPV Q5
Yes PAP 1x PAP Q10 PAP Q5 HPV Q5 PAP Q3 HPV Q5 HPV Q5
Upper-middle
income 1 (UMI1)
($4126–$8435)
No HPV 1x HPV Q10 HPV Q5 HPV Q5 HPV-VIA Q5 HPV-VIA Q5 HPV-VIA Q5
Yes PAP 1x PAP Q10 PAP Q5 HPV Q5 PAP Q3 HPV-VIA Q5 HPV-VIA Q5
Upper-middle
income 2 (UMI2)
($8436–$12745)
No HPV-VIA 1x HPV-VIA Q10 HPV-VIA Q5 HPV-VIA Q5 HPV-VIA Q5 HPV-VIA Q5 HPV-VIA Q5
Yes PAP 1x PAP Q10 PAP Q5 HPV-VIA Q5 PAP Q3 HPV-VIA Q5 HPV-VIA Q5
a HPV: human papillomavirus testing; HPV-VIA: HPV testing with visual inspection triage; PAP: Pap testing; VIA: visual inspection with acetic acid; 1x: Once
in a lifetime at age 35 years; Q10: screening at 10-year interval (at age 30, 40 years); Q5: screening at 5-year interval (at age 30, 35, 40, 45 years); Q3:
screening at 3-year interval (at age 30, 33, 36, 39, 42, 45, 48 years); $: 2013 US$.
b Existing cytology programs with >40% coverage (includes Argentina, Brazil, Colombia, Costa Rica, Dominican Republic, El Salvador, Hungary,
Kazakhstan, Mexico, Paraguay, Peru, Ukraine) [30,31].
doi:10.1371/journal.pone.0164000.t001
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To provide an upper bound on cost estimates, we assumed no loss-to-follow-up of screen-
positive women between visits for confirmatory diagnostic testing and/or treatment. Because
management algorithms for screen-positivewomen vary by setting, we made the following sim-
plifying assumptions across all countries: 1) visual inspectionwith acetic acid (VIA) and HPV
testing are followed by cryotherapy for eligible screen-positivewomen (i.e., a screen-and-treat
approach); 2) HPV testing with VIA triage for HPV-positive women (HPV-VIA) is followed by
cryotherapy for eligible women who screen positive on VIA (i.e., a screen-and-treat approach);
3) a proportion of women who screen positive with HPV and/or VIA testing are deemed ineligi-
ble for immediate treatment (5% of women with no lesion, 15% of women with CIN1, and 25%
of women with CIN2/3) and require a colposcopy/biopsy; 5) Pap testing is followed by colpos-
copy/biopsy for all screen-positivewomen; 6) women with histologically confirmedCIN1
receive cryotherapy, while women with histologically confirmedCIN2/3 receive LEEP.
Screening test performance parameters are displayed in Table E in S1 File. To capture costs
associated with screening, diagnosis, and treatment of precancer, CERVIVAC estimates the
number of true positives (women with CIN1 or CIN2/3 who screen positive) and the number
of false positives (women with no lesion who screen positive) based on screening test perfor-
mance and the prevalence of oncogenic HPV, CIN1 and CIN23. Due to limited data and varia-
tion in colposcopy performance by setting, we have assumed perfect colposcopy (i.e., 100%
sensitivity and specificity at the CIN1+ threshold) in each country.
To account for reduced lesion prevalence in scenarios with repeated screening, we derived
“attenuation factors” for both CIN1 and CIN2/3 lesions. We simulated VIA, Pap, and HPV test-
ing in the calibrated microsimulationmodels at 100% coverage of the target group of women
(aged 30 to 49 years), for each screening frequency considered. From model output we calcu-
lated the percent reduction in CIN1 and CIN2/3 lesions immediately prior to each screening
after the first. This percent reduction was averaged across the number of subsequent screenings,
and this average was subtracted from one to generate the “attenuation factor” associated with a
given screeningmodality and frequency. Thus, the attenuation factor is the ratio between the
prevalence of lesions at the first screening visit and the prevalence of lesions expected at all sub-
sequent screening visits. Attenuation factors are displayed in Table F in S1 File.
Cost input data
For vaccination, we includedHPV vaccination delivery costs and the price of the vaccine
under three scenarios in which we varied the per-dose price of the vaccine by income tier.
Sources of HPV vaccine price information included Gavi, the Vaccine Alliance, PAHO Revolv-
ing Fund (RF) and a report fromMédecins Sans Frontières (Table 2). We assumed Gavi-eligi-
ble countries would have access to the Gavi-negotiated prices in all years under all scenarios.
Similarly, we assumed all Latin America and Caribbean (LAC) region countries and South
Africa would access the PAHO RF price in all years under all scenarios, because these countries
have access to the PAHO RF (though not all use it). Prices for non-Gavi, non-LAC countries
were based on country income tiers. Under each scenario we assumed that vaccine pricing
would remain constant between 2015 and 2024, and that countries would remain in the same
income tier. The most optimistic (lowest cost) Scenario A is a two-tier scheme where all Gavi
countries access the Gavi price of US$4.55 per dose, all non-Gavi LMI1 countries access the
Gavi price as well, and all non-Gavi countries in income tier LMI2 or higher access a price
equal to the RF price of US$13.79 per dose. In alternative scenarios, prices for non-Gavi non-
RF countries were assumed to be higher (Scenarios B and C).
We identified data on HPV vaccination delivery cost per dose from the published literature
and restricted estimates to economic costs, defined as the cost of all resources used regardless
Resources Required for Cervical Cancer Prevention
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of payer [32–34]; unlike financial costs, economic costs include the salaries of health personnel
which have already been paid for prior to initiation of an HPV vaccination program, but still
represent an opportunity cost. When possible, we excluded start-up costs which would only be
relevant within the initial years of a program.We considered all deliverymechanisms, includ-
ing school-based, health center-based, and integrated outreach. All costs were converted to
2013 US$ using GDP deflators and exchange rates (Table G in S1 File). We assumed that deliv-
ery costs did not vary with vaccination coverage.
For screening-related costs, we included direct medical costs associated with screening,
diagnosis, and treatment of precancerous lesions. Procedures and assumed location of service
delivery are presented in Table H in S1 File. To estimate the unit cost of each procedure, we
identified available data from the published literature [9,35], unpublished data from PATH's
START-UP demonstration projects [3,36], and data from a pilot study in El Salvador [37]; as
such, primary data were available for the following countries: Ghana, El Salvador, India (n = 3
studies), Kenya, Nicaragua, Peru, Uganda, South Africa, and Thailand. All unit costs were con-
verted to 2013 US$ using GDP deflators and exchange rates (Table I in S1 File)[11].
To extrapolate primary data estimates for each vaccination and screening procedure to all
countries, we obtained the unit cost of a primary health center visit and a secondary outpatient
hospital visit in each country from theWHO-CHOICE costing tool [38]; the latest available
local currency unit estimates from 2008 were converted into 2013 US$ using GDP deflators
and exchange rates. We took the ratio of theWHO-CHOICE facility cost in CountryX to the
WHO-CHOICE facility cost in a country with primary data for a given procedure.We multi-
plied this ratio by the cost of the procedure in the primary data to obtain an estimate of the pro-
cedure cost in CountryX. We repeated this calculation for each primary data estimate
associated with a given procedure, and then took the average of extrapolated values to use in
analysis. By incorporatingWHO-CHOICE data, these extrapolated values explicitly take into
account the high correlation between a country's GDP per capita and health care costs. We
assumed that the HPV test was a tradable goodwith a standardized value of US$5 across all set-
tings, and thus did not apply WHO-CHOICE facility ratios to this value to obtain HPV screen-
ing costs; rather, we applied WHO-CHOICE ratios to the other direct medical cost
Table 2. HPV vaccine price per dose scenarios, by income tier.a
Income tier Vaccination scenariob
Scenario A Scenario B Scenario C
Low income (LI) (< $1045) 4.55 4.55 4.55
Lower-middle income 1 (LMI1) ($1046–$2585) 4.55 13.79 13.79
Lower-middle income 2 (LMI2) ($2586–$4125) 13.79 27.58 27.58
Upper-middle income 1 (UMI1) ($4126–$8435) 13.79 40 40
Upper-middle income 2 (UMI2) ($8436–$12745) 13.79 40 70
a $: 2013 US$. We assumed Gavi-eligible countries would have access to the Gavi-negotiated prices in all years under all scenarios. Similarly, we assumed
all Latin America and Caribbean (LAC) region countries and South Africa would access the PAHO Revolving Fund price in all years under all scenarios,
because these countries have access to the PAHO Revolving Fund (though not all use it). Prices for non-Gavi, non-LAC countries were based on country
income tiers.
b Vaccination Scenario A is a two-tier scheme where all Gavi-eligible and non-Gavi-eligible LMI1 countries access the Gavi price of US$4.55 per dose, while
all non-Gavi countries in income tier LMI2 or higher access a price equal to the PAHO Revolving Fund price of US$13.79 per dose. Vaccination Scenario B
applies the Gavi price to LI countries only, and the PAHO Revolving Fund price to LMI1 countries; LMI2 countries are assumed to receive twice the
Revolving Fund price, while UMI countries receive the best UMI price of US$40 per dose according to Me´decins Sans Frontières. Vaccination Scenario C is
similar to scenario B except UMI2 countries are subject to a higher price of US$70 per dose.
doi:10.1371/journal.pone.0164000.t002
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components of HPV testing (e.g., staff time, laboratory processing, other supplies) and added
the US$5 test cost afterward.We performed a sensitivity analysis in which we assumed the cost
of the HPV test ranged from US$2.50 to US$7.50, to estimate the potential impact of bulk pur-
chasing of HPV tests or a potentially higher market price. Results for the average HPV vaccine
delivery cost per dose, by income tier and Gavi eligibility, are shown in Table J in S1 File; unit
costs by screening, diagnostic, and precancer treatment procedure for each income tier are
shown in Table K in S1 File. Unit costs for each procedure are plotted against 2013 GDP per
capita in Figure A in S1 File.
Cost per woman of screening age
To calculate the average cost per woman of screening age under each screening scenario, we
assumed the total population size remained static over 10 years and was represented by the
total population of women aged 30 to 49 years in 2015. We divided the total cost of screening,
diagnostic confirmation, and treatment of precancer at full coverage from 2015 to 2024 by this
total population size of 30 to 49 year old women in 2015 to estimate the cost per woman of
screening age during the period of interest.
Results
The total cost of HPV vaccination from 2015 to 2024 by income tier and World Bank region,
for each roll-out strategy and vaccine pricing scenario, is presented in Table 3 (undiscounted;
discounted results are presented in Table L in S1 File). The total cost for immediate roll-out in
the optimistic pricing scenario (ScenarioA) is US$15.5 billion, or about US$1.55 billion per
year. About 58% of this cost is for the vaccine product itself. This scenario would vaccinate 513
million girls over 10 years at an average cost of US$30.19 per girl, ranging from US$12 per girl
in LI settings to US$59 per girl in UMI2 settings.With less favorable vaccine pricing (Scenario
C), the cost of immediate roll-out could be as much as US$24.2 billion, and the vaccine product
itself would represent 73% of this cost. A 5-year roll-out would reach about 415 million girls
and cost US$12.5 billion in the most optimistic pricing scenario (ScenarioA). A 10-year roll-
out would reach 286 million girls and cost US$8.6 billion in the most optimistic pricing sce-
nario (ScenarioA).
The total cost of cervical cancer screening, diagnostic testing, and treatment of precancerous
lesions from 2015 to 2024 by income tier and World Bank region, for each roll-out strategy
and screening scenario, is presented in Table 4 (undiscounted; discounted results are presented
in Table M in S1 File). With immediate roll-out, Scenario 1 (screening once at age 35) was the
least costly (US$9.0 billion). Scenario 2 (screening at ages 30 and 40) was the next least costly,
at a total cost of US$17.6 billion. Scenario 5 (high intensity screening with Pap) was the most
costly due to frequent Pap screening every three years in countries with existing cytology pro-
grams (US$42.3 billion); Scenario 6 (high intensity screening without Pap), in which triennial
Pap screening was replaced with HPV or HPV-VIA testing every 5 years, yielded a lower total
cost (US$29.4 billion). The vast majority of savings (78%) associated with switching from Sce-
nario 5 to Scenario 6 were in UMI2 countries, which include several populous countries (i.e.,
Brazil and Mexico) that were assumed to use HPV-VIA testing in Scenario 6. Despite the addi-
tional costs of a triage test with HPV-VIA, this screening test system yielded substantial savings
in diagnostic and treatment costs relative to Pap screening.
For all scenarios, immediate roll-out yielded the highest total costs over the 10-year period,
while 5-year roll-out reduced total costs by approximately 20% as scaling of screening and
treatment programs was spread over the first 5 years, and gradual roll-out over 10 years
reduced costs by approximately 45%.While the cost per year changes little once full coverage
Resources Required for Cervical Cancer Prevention
PLOS ONE | DOI:10.1371/journal.pone.0164000 October 6, 2016 8 / 20
Table 3. Total undiscounted cost of HPV vaccination from 2015 to 2024, by income tier, World Bank region, and vaccination scenario (2013 US$,
billions).a
Income tier or World Bank region Number of 10-year old girls in 2015, LMIC (% of total) Vaccination scenario
A B C
Immediate roll-outb, cost (% of total costs)
TOTAL 49,743,665 $15.5 B $23.5 B $24.2 B
By Income Tier
LI 9,868,831 (20%) $1.3 B (8) $1.3 B (5) $1.3 B (5)
LMI1 16,988,122 (34%) $2.6 B (17) $2.8 B (12) $2.8 B (11)
LMI2 7,610,480 (15%) $3.4 B (22) $5.5 B (23) $5.5 B (23)
UMI1 10,427,821 (21%) $5.6 B (36) $10.6 B (45) $10.6 B (44)
UMI2 4,848,411 (10%) $2.7 B (17) $3.3 B (14) $4.1 B (17)
By World Region
EAP 12,545,391 (25%) $5.8 B (37) $11.2 B (48) $11.4 B (47)
ECA 1,848,914 (4%) $1.0 B (6) $1.8 B (7) $2.3 B (10)
LAC 5,162,675 (10%) $2.7 B (17) $2.8 B (12) $2.8 B (11)
MENA 1,909,780 (4%) $0.8 B (5) $1.5 B (6) $1.5 B (6)
SA 15,897,310 (32%) $2.4 B (15) $2.4 B (10) $2.4 B (10)
SSA 12,379,595 (25%) $2.9 B (19) $3.9 B (17) $3.9 B (16)
By Gavi eligibility
Gavi-eligiblec 26,216,170 (53%) $3.8 B (24) $3.8 B (16) $3.8 B (16)
Non-Gavi eligible 23,527,495 (47%) $11.7 B (76) $19.7 B (84) $20.4 B (84)
5-year roll-outb, cost (% of total costs)
TOTAL 49,743,665 $12.5 B $19 B $19.5 B
By Income Tier
LI 9,868,831 (20%) $1 B (8) $1 B (5) $1 B (5)
LMI1 16,988,122 (34%) $2.1 B (17) $2.2 B (12) $2.2 B (11)
LMI2 7,610,480 (15%) $2.7 B (22) $4.5 B (24) $4.5 B (23)
UMI1 10,427,821 (21%) $4.5 B (36) $8.6 B (45) $8.6 B (44)
UMI2 4,848,411 (10%) $2.1 B (17) $2.6 B (14) $3.2 B (17)
By World Region
EAP 12,545,391 (25%) $4.6 B (37) $9.1 B (48) $9.2 B (47)
ECA 1,848,914 (4%) $0.8 B (6) $1.4 B (7) $1.9 B (10)
LAC 5,162,675 (10%) $2.1 B (17) $2.2 B (12) $2.2 B (11)
MENA 1,909,780 (4%) $0.7 B (5) $1.2 B (6) $1.2 B (6)
SA 15,897,310 (32%) $1.9 B (15) $1.9 B (10) $1.9 B (10)
SSA 12,379,595 (25%) $2.4 B (19) $3.2 B (17) $3.2 B (16)
By Gavi eligibility
Gavi-eligiblec 26,216,170 (53%) $3 B (24) $3 B (16) $3 B (16)
Non-Gavi eligible 23,527,495 (47%) $9.5 B (76) $15.9 B (84) $16.5 B (84)
10-year roll-outb, cost (% of total costs)
TOTAL 49,743,665 $8.6 B $13.1 B $13.5 B
By Income Tier
LI 9,868,831 (20%) $0.7 B (8) $0.7 B (5) $0.7 B (5)
LMI1 16,988,122 (34%) $1.5 B (17) $1.5 B (12) $1.5 B (11)
LMI2 7,610,480 (15%) $1.9 B (22) $3.1 B (24) $3.1 B (23)
UMI1 10,427,821 (21%) $3.1 B (36) $6.0 B (45) $6.0 B (44)
UMI2 4,848,411 (10%) $1.5 B (17) $1.8 B (14) $2.2 B (16)
By World Region
EAP 12,545,391 (25%) $3.2 B (37) $6.3 B (48) $6.4 B (47)
(Continued )
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of the target population is achieved, the yearly cost varies substantially by screening scenario
(Fig 1). Under Scenario 1 (screening once at age 35), yearly costs of 10-year roll-out range from
US$82million in 2015 to US$975 million in 2024, totaling US$5.1 billion for the 10-year period
during which more than 252 million women would be screened (relative to US$9.0 billion for
immediate roll-out, during which more than 440 million women would be screened).
The greatest proportion of the LMIC screening population resides in the UMI1 income tier
(35%), which account for 32% (Scenario 5) to 46% (Scenarios 2 and 3) of total costs.While 30%
of the LMIC screening population resides in the LMI1 income tier, these countries represent
only 12% of total costs under Scenario 1 (screening once at age 35) with immediate roll-out, due
to the use of the least costly screening test (i.e., VIA) and the relationship between directmedical
costs and GDP per capita. With a shift to HPV testing in LMI1 under Scenario 7 (HPV-based
screening at 5-year intervals), this income tier still represents only 21% of total costs with full
immediate coverage. The LI countries, comprising 11% of the LMIC population, incur only 2%
to 5% of the total screening and treatment costs under any scenario, due to the exclusive use of
VIA in these settings and low direct medical costs relative to other income tiers.
When stratified by World Bank region, the largest component of the LMIC population
resides in the East Asia and Pacific Region (39%), followed by South Asia (29%). Assuming
immediate roll-out, screening- and treatment-related costs in the East Asia and Pacific Region
account for 29% (Scenario 5) to 50% (Scenario 4) of total costs; South Asia accounts for only
9% (Scenario 3) to 19% (Scenario 6) of total screening and treatment-related costs, due to the
primarily LI and LMI1 countries that comprise this region. Screening- and treatment-related
costs in Sub-Saharan Africa (which is home to 13% of women of screening age in LMIC)
account for 8% (Scenarios 1, 2, 3, and 5) to 11% (Scenarios 6 and 7) of total costs.
The relative distribution of screening, diagnostic, and treatment costs is displayed in Fig 2.
Scenarios 1 (screening once at age 35) and 7 (HPV-based screening at 5-year intervals in all but
LI countries) represent the extremes of this distribution. In Scenario 1, 49% of total costs are
attributable to screening tests. BecauseHPV-VIA is offered only in UMI2 countries without
Table 3. (Continued)
Income tier or World Bank region Number of 10-year old girls in 2015, LMIC (% of total) Vaccination scenario
A B C
ECA 1,848,914 (4%) $0.5 B (6) $1 B (7) $1.3 B (9)
LAC 5,162,675 (10%) $1.5 B (17) $1.5 B (11) $1.5 B (11)
MENA 1,909,780 (4%) $0.5 B (5) $0.8 B (6) $0.8 B (6)
SA 15,897,310 (32%) $1.3 B (15) $1.3 B (10) $1.3 B (10)
SSA 12,379,595 (25%) $1.7 B (19) $2.2 B (17) $2.2 B (16)
By Gavi eligibility
Gavi-eligiblec 26,216,170 (53%) $2.1 B (24) $2.1 B (16) $2.1 B (16)
Non-Gavi eligible 23,527,495 (47%) $6.5 B (76) $11 B (84) $11.4 B (84)
a Gavi: Gavi, the Vaccine Alliance; LMIC: low- and middle-income countries; LI: Low income; LMI1: Lower-middle income tier 1; LMI2: Lower-middle income
tier 2; UMI1: Upper-middle income tier 1; UMI2: Upper-middle income tier 2; EAP: East Asia & Pacific; ECA: Europe & Central Asia; LAC: Latin America &
Caribbean; MENA: Middle East & North Africa; SA: South Asia; SSA: Sub-Saharan Africa.
b Immediate roll-out: Full coverage (100%) of the target population from 2015 to 2024; Rapid roll-out: 20% coverage in 2015, 40% coverage in 2016, 60%
coverage in 2017, 80% coverage in 2018, and 100% coverage of the target population from 2019 to 2024; Gradual roll-out: 10% coverage in 2015, 20%
coverage in 2016, 30% coverage in 2017, 40% coverage in 2018, 50% coverage in 2019, 60% coverage in 2020, 70% coverage in 2021, 80% coverage in
2022, 90% coverage in 2023, and 100% coverage of the target population in 2024.
c Eligible for assistance from Gavi, the Vaccine Alliance, in 2014. See Table A in the S1 File for listing of 43 countries.
doi:10.1371/journal.pone.0164000.t003
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Table 4. Total undiscounted cost of cervical cancer screening and treatment from 2015 to 2024, by income tier, World Bank region, and screening
scenario (2013 US$, millions).a
Income tier or World
Bank region
Number of women aged 30–49 years in
2015, LMIC (% of total)
Screening scenario
1 2 3 4 5 6 7
Immediate roll-outb, cost (% of total costs)
TOTAL 760,402,598 $9.0 B $17.6 B $36.6 B $31.1 B $42.3 B $29.4 B $29.2 B
By Income Tier
LI 84,739,921 (11%) $0.2 B
(3)
$0.5 B
(3)
$0.8 B 2) $0.8 B (3) $1.4 B (3) $1.4 B (5) $1.4 B (5)
LMI1 230,936,378 (30%) $1.0 B
(11)
$2.0 B
(12)
$3.8 B
(10)
$3.8 B
(12)
$6.4 B
(15)
$6.4 B
(22)
$6.2 B
(21)
LMI2 94,895,600 (12%) $1.1 B
(12)
$2.0 B
(12)
$6.1 B
(17)
$6.0 B
(20)
$5.7 B
(13)
$5.1 B
(18)
$5.1 B
(18)
UMI1 263,137,970 (35%) $4.1 B
(45)
$8.0 B
(46)
$16.0 B
(46)
$15.3 B
(49)
$13.5 B
(32)
$11.2 B
(38)
$11.2 B
(39)
UMI2 86,992,729 (11%) $2.5 B
(28)
$5.1 B
(29)
$9.8 B
(26)
$5.2 B
(16)
$15.3 B
(36)
$5.2 B
(18)
$5.2 B
(18)
By World Region
EAP 295,355,455 (39%) $3.8 B
(42)
$6.9 B
(39)
$15.4 B
(42)
$15.4 B
(50)
$12.2 B
(29)
$12.2 B
(41)
$12.1 B
(41)
ECA 39,367,836 (5%) $0.8 B
(9)
$1.6 B
(9)
$3.1 B (8) $2.6 B (8) $3.8 B (9) $2.5 B (8) $2.5 B (9)
LAC 82,566,777 (11%) $2.6 B
(29)
$5.2 B
(30)
$10.0 B
(27)
$5.0 B
(16)
$16.3 B
(39)
$4.8 B
(16)
$4.8 B
(16)
MENA 27,105,360 (4%) $0.3 B
(3)
$0.6 B
(4)
$1.6 B (4) $1.6 B (5) $1.2 B (3) $1.2 B (4) $1.2 B (4)
SA 220,923,612 (29%) $0.9 B
(10)
$1.8 B
(10)
$3.5 B (9) $3.5 B
(11)
$5.6 B
(13)
$5.6 B
(19)
$5.4 B
(19)
SSA 95,083,558 (13%) $0.7 B
(8)
$1.5 B
(8)
$3.1 B (8) $3.1 B
(10)
$3.2 B (8) $3.2 B
(11)
$3.3 B
(11)
5-year roll-outb, cost (% of total costs)
TOTAL 760,402,598 $7.4 B $14.1 B $29.4 B $25.0 B $34.0 B $23.7 B $23.5 B
By Income Tier
LI 84,739,921 (11%) $0.2 B
(3)
$0.4 B
(3)
$0.7 B (2) $0.7 B (3) $1.1 B (3) $1.1 B (5) $1.1 B (5)
LMI1 230,936,378 (30%) $0.8 B
(11)
$1.6 B
(12)
$3.1B
(11)
$3.1 B
(12)
$5.2 B
(15)
$5.2 B
(22)
$5.1 B
(22)
LMI2 94,895,600 (12%) $0.9 B
(12)
$1.6 B
(12)
$4.9 B
(17)
$4.8 B
(20)
$4.6 B
(13)
$4.2 B
(18)
$4.2 B
(18)
UMI1 263,137,970 (35%) $3.4 B
(46)
$6.4 B
(45)
$12.8 B
(43)
$12.2 B
(49)
$10.8 B
(31)
$9.0 B
(38)
$9.0 B
(38)
UMI2 86,992,729 (11%) $2.0 B
(27)
$4.1 B
(29)
$7.9 B
(26)
$4.2 B
(16)
$12.2 B
(36)
$4.2 B
(18)
$4.2 B
(18)
By World Region
EAP 295,355,455 (39%) $3.1 B
(42)
$5.5 B
(39)
$12.3 B
(42)
$12.3 B
(49)
$9.7 B
(29)
$9.7 B
(41)
$9.6 B
(41)
ECA 39,367,836 (5%) $0.6 B
(9)
$1.3 B
(9)
$2.4 B (8) $2.1 B (8) $3.1 B (9) $2.0 B (8) $2.0 B (9)
LAC 82,566,777 (11%) $2.1 B
(28)
$4.2 B
(30)
$8.0 B
(27)
$4.0 B
(16)
$13.1 B
(38)
$3.8 B
(16)
$3.8 B
(16)
MENA 27,105,360 (4%) $0.2 B
(3)
$0.5 B
(4)
$1.3 B (4) $1.3 B (5) $1.0 B (3) $1.0 B (4) $1.0 B (4)
SA 220,923,612 (29%) $0.7 B
(10)
$1.4 B
(10)
$2.8 B
(10)
$2.8 B
(11)
$4.5 B
(13)
$4.5 B
(19)
$4.4 B
(19)
(Continued )
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existing Pap programs, triage tests account for<1% of total costs. The reliance on Pap screen-
ing in the 12 countries with existing programs results in 20% of total costs being spent on
colposcopy. Cryotherapy accounts for 28% of costs, and LEEP for 4%. The shift to HPV-based
testing in all but LI countries under Scenario 7 raises the relative contribution of screening
costs to 67%, with the relative share of LMI1 and LMI2 countries increasing as VIA (and Pap,
in El Salvador, Paraguay, and Ukraine) is replaced by HPV testing in these income tiers. The
proportional cost of triage tests increases slightly to 4%, as HPV-VIA is adopted in all UMI
countries, while the reduced reliance on Pap testing leads to a reduced contribution of colpos-
copy to total costs (5%). Cryotherapy and LEEP account for 25% of total costs, as the number
of women treated decreases as a result of HPV-VIA triage testing.
Table 4. (Continued)
Income tier or World
Bank region
Number of women aged 30–49 years in
2015, LMIC (% of total)
Screening scenario
1 2 3 4 5 6 7
SSA 95,083,558 (13%) $0.6 B
(8)
$1.2 B
(9)
$2.5 B (9) $2.5 B
(10)
$2.6 B (8) $2.6 B
(11)
$2.7 B
(11)
10-year roll-outb, cost (% of total costs)
TOTAL 760,402,598 $5.1 B $9.7 B $20.3 B $17.2 B $23.4 B $16.3 B $16.2 B
By Income Tier
LI 84,739,921 (11%) $0.1 B
(3)
$0.3 B
(3)
$0.5 B (2) $0.5 B (3) $0.8 B (3) $0.8 B (5) $0.8 B (5)
LMI1 230,936,378 (30%) $0.6 B
(11)
$1.1 B
(12)
$2.2 B
(11)
$2.2 B
(13)
$3.6 B
(15)
$3.6 B
(22)
$3.5 B
(22)
LMI2 94,895,600 (12%) $0.6 B
(12)
$1.1 B
(12)
$3.4 B
(17)
$3.4 B
(20)
$3.2 B
(13)
$2.9 B
(18)
$2.9 B
(18)
UMI1 263,137,970 (35%) $2.4 B
(47)
$4.3 B
(45)
$8.8 B
(43)
$8.4 B
(49)
$7.4 B
(31)
$6.2 B
(38)
$6.2 B
(38)
UMI2 86,992,729 (11%) $1.4 B
(27)
$2.8 B
(29)
$5.4 B
(26)
$2.9 B
(16)
$8.4 B
(36)
$2.9 B
(18)
$2.9 B
(18)
By World Region
EAP 295,355,455 (39%) $2.2 B
(43)
$3.8 B
(39)
$8.5 B
(42)
$8.5 B
(49)
$6.7 B
(29)
$6.7 B
(41)
$6.6 B
(41)
ECA 39,367,836 (5%) $0.4 B
(9)
$0.9 B
(9)
$1.7 B (8) $1.4 B (8) $2.1 B (9) $1.4 B (8) $1.4 B (9)
LAC 82,566,777 (11%) $1.4 B
(28)
$2.9 B
(30)
$5.5 B
(27)
$2.8 B
(16)
$9.0 B
(38)
$2.6 B
(16)
$2.6 B
(16)
MENA 27,105,360 (4%) $0.2 B
(3)
$0.4 B
(4)
$0.9 B (4) $0.9 B (5) $0.7 B (3) $0.7 B (4) $0.7 B (4)
SA 220,923,612 (29%) $0.5 B
(10)
$1.0 B
(10)
$2.0 B
(10)
$2.0 B
(11)
$3.1 B
(13)
$3.1 B
(19)
$3.0 B
(19)
SSA 95,083,558 (13%) $0.4 B
(8)
$0.8 B
(9)
$1.8 B (9) $1.8 B
(10)
$1.8 B (8) $1.8 B
(11)
$1.9 B
(11)
a LMIC: low- and middle-income countries; LI: Low income; LMI1: Lower-middle income tier 1; LMI2: Lower-middle income tier 2; UMI1: Upper-middle
income tier 1; UMI2: Upper-middle income tier 2; EAP: East Asia & Pacific; ECA: Europe & Central Asia; LAC: Latin America & Caribbean; MENA: Middle
East & North Africa; SA: South Asia; SSA: Sub-Saharan Africa.
b Immediate roll-out: Full coverage (100%) of the target population from 2015 to 2024; 5-year roll-out: 20% coverage in 2015, 40% coverage in 2016, 60%
coverage in 2017, 80% coverage in 2018, and 100% coverage of the target population from 2019 to 2024; 10-year roll-out: 10% coverage in 2015, 20%
coverage in 2016, 30% coverage in 2017, 40% coverage in 2018, 50% coverage in 2019, 60% coverage in 2020, 70% coverage in 2021, 80% coverage in
2022, 90% coverage in 2023, and 100% coverage of the target population in 2024.
doi:10.1371/journal.pone.0164000.t004
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Fig 1. Screening and treatment costs by screening scenario, year and roll-out strategy (2013 US$, millions). Each panel displays the cost (y-axis,
2013 US$) in each year (x-axis) associated with immediate (blue line), 5-year (red line), and 10-year (green line) roll-out in each screening and treatment
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The average cost per woman of screening age for the 10-year period from 2015 to 2024,
assuming full coverage of the target population (i.e., immediate roll-out), is displayed in
Table 5. Under Scenario 1 (screening once at age 35), the cost per woman of screening age is
US$11.87; this increases to US$23.13 when women are screened at ages 30 and 40 years (Sce-
nario 2). The highest cost per woman of screening age is associated with Scenario 5 (higher
intensity screening with Pap), at US$55.59.With a shift toward HPV-based screening, this cost
is reduced to US$38.65 when VIA is still offered in LI and LMI1 countries (Scenario 6). A shift
to HPV-based screening in all but the LI countries (Scenario 7) has only a marginal impact on
the cost per woman of screening age, which falls slightly to US$38.41.When we consider time
preferences and apply a discount rate of 3% per year, the cost per woman of screening age is
roughly 15% lower under each screening scenario.
Providing both vaccination and screening in a comprehensive cervical cancer prevention
program would cost US$13.7 billion with a 10-year roll-out strategy, favorable vaccine pricing
(ScenarioA), and screening once at age 35 (Scenario 1); this would cover the cost of vaccinating
286 million girls and screeningmore than 250 million women. Under the least favorable vac-
cine pricing (ScenarioC), this total cost would rise to US$18.6 billion. Immediate roll-out of
vaccination and Scenario 7 (HPV-based screening at 5-year intervals in LMI1 and above, and
VIA at 3-year intervals in LI settings) would cost US$44.7 billion over the 10 years in the most
favorable vaccine pricing scenario (A), and US$53.4 billion in the least favorable vaccine pric-
ing scenario (C).
We performed a sensitivity analysis in which the assumed cost of the HPV test was varied
from US$2.50 to US$7.50 in Scenario 7 (HPV-based screening in all but LI countries), relative
to the base case value of US$5. At an HPV test cost of US$2.50, total costs of screening associ-
ated with immediate roll-out were reduced from US$29.2 billion to US$25.5 billion. The cost
per woman of screening age fell from US$38.41 to US$33.58. At a higher HPV test cost of US
$7.50, the total cost of screening with immediate roll-out increased to US$32.9 billion, and the
cost per woman of screening age rose to US$43.23.
Discussion
To the best of our knowledge, this study provides the first estimate of a global cost for cervical
cancer prevention in LMIC, including HPV vaccination of young adolescent girls and screen-
ing and preventive treatment of women aged 30 to 49 years. We consideredmultiple policy sce-
narios—3 alternate vaccine pricing assumptions, 7 screening test and frequency assumptions,
and 3 roll-out strategies—to capture a reasonable range of costs associated with primary and
secondary prevention of cervical cancer in LMIC.While the immediate roll-out strategy is not
realistic, we present it as an upper bound that might represent spending for a fully scaled pro-
gram.We found that from years 2015 to 2024 HPV vaccination would cost from US$8.6 billion
to US$24.2 billion, depending on vaccine price scenario and speed of roll-out. In Gavi-eligible
countries, the cost of vaccination would range fromUS$2.1 billion to US$3.8 billion, depending
on the speed of roll-out. The total cost of screening and precancer treatment over this interval,
which depends upon the screening scenario and speed of roll-out, would range from US$5.1
billion to either US$29.4 billion (if countries relying on Pap switched to HPV-based screening)
or US$42.3 billion (if countries with existing Pap programs continued with Pap-based
scenario: Scenario 1, screening once at age 35 (panel A); Scenario 2, screening at a 10-year interval at age 30 and 40(panel B); Scenario 3, low intensity
screening, with Pap testing in countries with existing cytology programs (panel C); Scenario 4, low intensity screening without Pap testing (panel D);
Scenario 5, high intensity screening with Pap testing in countries with existing cytology programs (panel E); Scenario 6, high intensity screening without
Pap testing (panel F); and Scenario 7, HPV-based screening in all but the lowest income tier (panel G). Roll-out assumptions are described in the Methods.
doi:10.1371/journal.pone.0164000.g001
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Fig 2. Distribution of cervical cancer screening, diagnostic, and treatment costs for Screening Scenario 1 (once in a lifetime
screening) and Screening Scenario 7 (HPV-based screening in Lower-middle income tier 1 and above), immediate roll-out. Bars display
the proportion of total costs associated with each procedure for Scenario 1, screening once at age 35 (upper panel) and Scenario 7, HPV-based
screening in all but the lowest income tier (lower panel): screening tests (blue); cryotherapy (red); colposcopy/biopsy (green); loop
electrosurgical excision procedure (LEEP) (dark purple), and triage tests (turquoise). The distribution of costs is presented for all countries (top
bar) and by income tier.
doi:10.1371/journal.pone.0164000.g002
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screening). For screening once at age 35, the cost in LI and LMI1 countries that may be depen-
dent on foreign aid to finance screening would range from US$0.7 billion to US$1.2 billion,
depending on the speed of roll-out.
In LMIC, the 10-year roll-out of HPV vaccination and cervical cancer screening programs
that screen women once at age 35 had an associated cost of US$13.7 billion over the next 10
years; the average cost per girl vaccinated would be US$30.19 and the average cost per woman
of screening age during this periodwould be US$11.87. HPV vaccination of young girls and
screening of women at ages 30 and 40 years with a 10-year roll-out had an associated cost of
US$18.3 billion (cost per woman of screening age: US$23.13).With more frequent, HPV-
based screening, the cost per woman of screening age may reach US$38.41. A shift to HPV-
based testing may provide some cost savings relative to Pap testing if screening frequency can
be reduced from every 3 to every 5 years. Furthermore, HPV with VIA triagemay reduce over-
all costs relative to HPV testing by sending fewer women to treatment.
There are several limitations to this analysis. In the absence of country-specific screening
guidelines in most settings, we made simplifying assumptions regarding screening protocols
and management of screen-positivewomen that assumed full capacity to provide treatment of
precancer and did not account for the potential presence of multiple screeningmodalities in
any given country; loss-to-follow-up of screen-positivewomen; varyingmanagement strategies
by country; or imperfect performance of colposcopy. We focused upon screening and triage
algorithms recommended by WHO guidelines [10], and thus while we considered HPV testing
followed by triage with VIA, we did not consider a scenario where HPV-positive women were
triaged based on Pap testing, although this is a possible path countries with existing Pap pro-
grams might consider. We assumed women were only eligible for screening at precise ages over
the 10-year time horizon; thus, costs do not reflect the same frequency of screening in every
woman’s lifetime, but rather the number of screenings that fall within the 10-year horizon
based on the population age structure.We have not explicitly consideredmore frequent
Table 5. Cost, over 10 years, per woman of screening age in 2015, by screening scenario (2013 US$).a
Screening scenario
Income tier 1 2 3 4 5 6 7
Cost per woman of screening age, undiscounted
All 11.87 23.13 48.15 40.93 55.59 38.65 38.41
LI 2.78 5.48 10.02 10.02 16.44 16.44 16.44
LMI1 4.49 8.79 16.64 16.64 27.87 27.87 27.06
LMI2 11.21 21.31 64.28 63.19 59.71 54.19 54.19
UMI1 15.74 30.32 60.90 58.00 51.41 42.74 42.74
UMI2 29.30 58.54 112.68 59.51 175.33 59.51 59.51
Cost per woman of screening age, discounted
All 10.07 19.72 41.03 34.87 47.36 32.92 32.71
LI 2.35 4.64 8.49 8.49 13.93 13.93 13.93
LMI1 3.81 7.47 14.13 14.13 23.68 23.68 22.98
LMI2 9.54 18.13 54.69 53.76 50.82 46.10 46.10
UMI1 13.31 25.90 51.97 49.50 43.87 36.48 36.48
UMI2 24.96 49.90 96.05 50.71 149.49 50.71 50.71
a: LI: Low income; LMI1: Lower-middle income tier 1; LMI2: Lower-middle income tier 2; UMI1: Upper-middle income tier 1; UMI2: Upper-middle income tier
2. Cost per woman of screening age is defined as the total cost of screening, diagnostic confirmation, and treatment of precancer at full coverage from 2015
to 2024 divided by the total population of 30 to 49 year old women in 2015. Calculations assume immediate roll-out.
doi:10.1371/journal.pone.0164000.t005
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screening in women with HIV or in areas with high endemic HIV infection, althoughWHO
guidelines recommend routine screening within 3 years [10]; however, we considered VIA
every three years in LI and LMI1 (Scenarios 5 and 6), where the burden of HIV is greatest. In
the absence of country-specificepidemiologic data in many settings, we relied upon model-
based extrapolation techniques, including multivariate regression (to predict HPV prevalence)
and a calibrated microsimulationmodel (to predict lesion prevalence); there remains uncer-
tainty in these estimates due to potential issues with quality of epidemiologic data and microsi-
mulation model structure. Because published and primary cost data on HPV vaccine delivery
and cervical cancer screening and treatment are limited to a handful of settings, we extrapo-
lated these cost data by using theWHO-CHOICE tool [38]; due to inconsistencies in cost
reporting across the literature, we cannot be certain that the published and primary data cost
estimates we used contain comparable components. We attempted to address this by consider-
ing all available data that was described in adequate detail, and we used the average of extrapo-
lated values to account for variability and uncertainty.
This study provides much-needed cost estimates for HPV vaccination and cervical cancer
screening, yet important questions remain. First, further data are needed to determine the pro-
grammatic investment costs that may be necessary to achieve high coverage levels of screening
and vaccination; current data are insufficient to establish the point at which economies of scale
may be counterbalanced by increasing programmatic costs of achieving high coverage. Pro-
grammatic costs of training health providers and providing quality assurance may be substan-
tial, and will likely vary by procedure. Second, the HPV vaccine delivery costs we considered
were primarily from demonstration projects; further data on the costs of delivery with national
scale-up are needed. Third, the impact of future events such as patent expiration, competition
from second-generation vaccines, or licensing agreements obtained by developing country vac-
cine manufacturers is uncertain [39]; the impact of the U.S. Food and Drug Administration’s
recent approval of an HPV 9-valent vaccine on the price of first generation vaccines and pros-
pects for generic manufacturing or voluntary licensing deals is unclear. Fourth, while we found
that HPV testing with VIA triage of HPV-positive women may lead to lower total costs than
HPV testing alone due to fewer women being referred to treatment, data on performance of
HPV-VIA triage suggests a low sensitivity for CIN2+ [40,41], which may compromise health
gains associated with screening and treatment.
In 2015, US$36.4 billion of development assistance for health was disbursed [42]. Of this,
US$10.8 billion was allocated for HIV/AIDS,US$6.5 billion for child and newbornhealth, and
US$3.6 billion for maternal health. By comparison, the present study found that the average
annual cost for screening women once at age 35 would be approximately US$900 million;
annual costs of HPV vaccination for all 10-year old girls (Vaccination Scenario A) would be
US$1.55 billion. Decisionmakers will need to consider additional data on the health impact
and relative cost-effectiveness of cervical cancer prevention strategies in relation to interven-
tions for competing health priorities to determine the best value for public health dollars.
This study provides the first estimate of a price tag for comprehensive cervical cancer pre-
vention in LMIC, including HPV vaccination of pre-adolescent girls and screening and treat-
ment of women aged 30 to 49 years. In 2015, there were nearly 50 million 10-year-old girls and
760 million women of screening age in LMIC. For donors who fund Gavi, the Vaccine Alliance,
the total cost of HPV vaccination in Gavi-eligible countries over 10 years is estimated at US
$2.1 to $3.8 billion. In countries that are not eligible for Gavi assistance, the total cost of HPV
vaccination is estimated at US$6.5 billion to US$20.4 billion, demonstrating the potential
impact of vaccine price negotiations in middle-income countries. For those who support the
health budgets of LI and LMI countries, the total cost of screening and treatment of precancer
is estimated at US$0.7 to US$7.8 billion.We hope this analysis will catalyze the current policy
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dialogue to expediently secure necessary resources and facilitate country-level discourse on
strengthening health infrastructure, identifying preferences for vaccine deliverymechanism
and screening test, gathering setting-specific comparative and cost-effectiveness data, and
determining timing of program introduction.
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